Toggle navigation
Search
Tree View
MeSH on Demand
MeSH 2025
About
Suggestions
Contact Us
Sorafenib
MeSH Descriptor Data 2024
Details
Qualifiers
MeSH Tree Structures
Concepts
MeSH Heading
Sorafenib
Tree Number(s)
D02.065.950.681.757
D02.455.426.559.389.703.757
D03.066.515.530.750
D03.383.725.547.530.750
Unique ID
D000077157
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000077157
Scope Note
A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in
ANGIOGENESIS
, including
RAF KINASES
and
VEGF RECEPTORS
. It is used in the treatment of advanced
RENAL CELL CARCINOMA
and
HEPATOCELLULAR CARCINOMA
, and for treatment of
THYROID CARCINOMA
refractory to radioactive iodine therapy.
Entry Term(s)
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 545-9085
BAY-545-9085
BAY-673472
Nexavar
Sorafenib N-Oxide
Sorafenib Tosylate
Pharm Action
Antineoplastic Agents
Protein Kinase Inhibitors
Related Numbers
5T62Q3B36J
5XYK65KIGD
CAS Type 1 Name
2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-
Public MeSH Note
2019; SORAFENIB was indexed under NIACINAMIDE and PHENYLUREA COMPOUNDS 2014-2018, and under BENZENESULFONATES and PYRIDINES 2003-2013
History Note
2019 (2003)
Date Established
2019/01/01
Date of Entry
2018/07/09
Revision Date
2020/05/27
Allowable Qualifiers
administration & dosage (AD)
adverse effects (AE)
agonists (AG)
analogs & derivatives (AA)
analysis (AN)
antagonists & inhibitors (AI)
blood (BL)
cerebrospinal fluid (CF)
chemical synthesis (CS)
chemistry (CH)
classification (CL)
economics (EC)
history (HI)
immunology (IM)
isolation & purification (IP)
metabolism (ME)
pharmacokinetics (PK)
pharmacology (PD)
poisoning (PO)
radiation effects (RE)
standards (ST)
supply & distribution (SD)
therapeutic use (TU)
toxicity (TO)
urine (UR)
Organic Chemicals [D02]
Amides [D02.065]
Urea [D02.065.950]
Phenylurea Compounds [D02.065.950.681]
Carbanilides [D02.065.950.681.202]
Celiprolol [D02.065.950.681.241]
Diflubenzuron [D02.065.950.681.280]
Diuron [D02.065.950.681.397]
Linuron [D02.065.950.681.515]
Sorafenib [D02.065.950.681.757]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Benzene Derivatives [D02.455.426.559.389]
Phenylurea Compounds [D02.455.426.559.389.703]
Carbanilides [D02.455.426.559.389.703.202]
Celiprolol [D02.455.426.559.389.703.241]
Diflubenzuron [D02.455.426.559.389.703.280]
Diuron [D02.455.426.559.389.703.397]
Linuron [D02.455.426.559.389.703.515]
Sorafenib [D02.455.426.559.389.703.757]
Heterocyclic Compounds [D03]
Acids, Heterocyclic [D03.066]
Nicotinic Acids [D03.066.515]
Niacinamide [D03.066.515.530]
6-Aminonicotinamide [D03.066.515.530.248]
Nicorandil [D03.066.515.530.498]
Nikethamide [D03.066.515.530.500]
Sorafenib [D03.066.515.530.750]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyridines [D03.383.725]
Nicotinic Acids [D03.383.725.547]
Niacinamide [D03.383.725.547.530]
6-Aminonicotinamide [D03.383.725.547.530.248]
Nicorandil [D03.383.725.547.530.498]
Nikethamide [D03.383.725.547.530.500]
Sorafenib [D03.383.725.547.530.750]
Expand All
Collapse All
Sorafenib
Preferred
Concept UI
M0446095
Related Numbers
5T62Q3B36J
5XYK65KIGD
Scope Note
A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in
ANGIOGENESIS
, including
RAF KINASES
and
VEGF RECEPTORS
. It is used in the treatment of advanced
RENAL CELL CARCINOMA
and
HEPATOCELLULAR CARCINOMA
, and for treatment of
THYROID CARCINOMA
refractory to radioactive iodine therapy.
Terms
Sorafenib
Preferred Term
Term UI
T000937070
Date
12/01/2017
LexicalTag
NON
ThesaurusID
BAY 43-9006
Narrower
Concept UI
M0446096
Terms
BAY 43-9006
Preferred Term
Term UI
T533756
Date
02/26/2003
LexicalTag
LAB
ThesaurusID
NLM (2003)
Sorafenib Tosylate
Narrower
Concept UI
M0493144
Terms
Sorafenib Tosylate
Preferred Term
Term UI
T000937075
Date
12/01/2017
LexicalTag
NON
ThesaurusID
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
Term UI
T000938933
Date
01/11/2018
LexicalTag
NON
ThesaurusID
NLM (2019)
Nexavar
Narrower
Concept UI
M0493145
Terms
Nexavar
Preferred Term
Term UI
T662665
Date
12/21/2005
LexicalTag
TRD
ThesaurusID
NLM (2005)
BAY 545-9085
Narrower
Concept UI
M0536239
Terms
BAY 545-9085
Preferred Term
Term UI
T752283
Date
06/04/2009
LexicalTag
LAB
ThesaurusID
NLM (2009)
BAY-545-9085
Term UI
T752284
Date
06/04/2009
LexicalTag
LAB
ThesaurusID
NLM (2009)
Sorafenib N-Oxide
Narrower
Concept UI
M000639469
Terms
Sorafenib N-Oxide
Preferred Term
Term UI
T000937073
Date
12/01/2017
LexicalTag
NON
ThesaurusID
BAY-673472
Narrower
Concept UI
M000639471
Terms
BAY-673472
Preferred Term
Term UI
T000937074
Date
12/01/2017
LexicalTag
NON
ThesaurusID
FDA SRS (2018)
page delivered in 0.16s